GlassScriptPhysician profile
Katherine Laura Tison
NPI 1740676022
$8,693.45
in general payments reported to CMS, 2019-2025
30 companies · $2,088 in 2025
The $2,088 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $700 · 2021: $986 · 2022: $1,388 · 2023: $1,421 · 2024: $2,109 · 2025: $2,088.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,500 · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,500.01 |
| Education | $119.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,574.11 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,413.21 | 2021-2025 | Fasenra, Airsupra, Tezspire |
| Csl Behring | $865.23 | 2021-2025 | Hizentra, Andembry, Haegarda |
| Glaxosmithkline, LLC. | $811.49 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $777.09 | 2021-2025 | Dupixent |
| Grifols USA, LLC | $437.12 | 2021-2025 | Xembify, Prolastin-C Liquid |
| Genentech USA, INC. | $379.16 | 2022-2025 | Xolair |
| Biocryst US Sales Co., LLC | $359.15 | 2021-2025 | Orladeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $277.13 | 2022-2025 | Takhzyro, Cuvitru, Hyqvia |
| Teva Pharmaceuticals USA, INC. | $214.60 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $190.60 | 2021-2025 | |
| Amgen INC. | $188.95 | 2021-2025 | Tezspire |
| Optinose US, INC. | $171.47 | 2021-2025 | |
| Aimmune Therapeutics, INC. | $159.03 | 2021-2022 | |
| Ars Pharmaceuticals Operations, INC. | $130.91 | 2025 | Neffy |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $117.22 | 2022-2025 | |
| Leo Pharma INC. | $108.71 | 2023-2024 | Adbry |
| Kaleo, INC. | $95.73 | 2022-2023 | Auvi-Q |
| Pharming Healthcare, INC. | $81.18 | 2022-2025 | Ruconest |
| Covis Pharma Gmbh | $65.46 | 2021 | |
| Alk-Abello, INC | $65.00 | 2021 | |
| Aytu Biopharma, INC. | $57.90 | 2021-2023 | Karbinal |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.78 | 2021-2022 | |
| Blueprint Medicines Corporation | $26.36 | 2024 | Ayvakit |
| Arcutis Biotherapeutics, INC. | $22.79 | 2025 | Zoryve |
| Mylan Specialty L.P. | $19.63 | 2021 | |
| Uswm, LLC | $17.00 | 2021 | |
| Lilly USA, LLC | $16.47 | 2025 | Ebglyss |
| Merck Sharp & Dohme LLC | $14.46 | 2023 | |
| Organon LLC | $9.51 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Tison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.